Please login to the form below

Not currently logged in
Email:
Password:

Recentin goes into phase three studies

Recentin, AstraZeneca's developmental cancer drug is to move into phase III clinical trails in first line metastatic colorectal cancer

Recentin, AstraZeneca's (AZ) developmental cancer drug is to move into phase III clinical trails in first line metastatic colorectal cancer.

A phase II review by the Horizon Independent Data Monitoring committee concluded that Recentin had met pre-requisite criteria to move into the next stage of trails.

Colorectal cancer is the third most common from of cancer affecting 945,000 people worldwide, with 492,000 being reported annually.

John Patterson, AZ's executive director for development, said: ìGiven there is such a high unmet patient need for more effective treatments in cancer, we are pleased that the Horizon colorectal cancer programme has met its pre-defined criteria to continue into phase III.

However, the National Cancer Institute of Canada Clinical Trails Group (NCIC-CTG) that Recentin will not be continuing into phase III of their trails of Recentin in non-small cell lung cancer (NSCLC).

Patterson said: "AZ supports the NCIC-CTG's recommendation and is working with them to understand the data more fully in NSCLC."

Recentin is being trailed for use in treatment of glioblastoma, and other tumours.

27th February 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell - Cake

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics